Valink Therapeutics develops next-generation bispecific antibody-drug conjugates (ADCs) designed for enhanced tumor targeting and reduced off-target toxicity. Their proprietary V-Gate approach enables continuous, tunable drug activation based on multiple molecular targets present on cancer cells. This technology aims to create more effective oncology therapeutics capable of treating diseases resistant to current options.
Funding
$125K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The development of antibody-drug conjugates (ADCs) for solid tumors is hindered by the difficulty in differentiating between malignant and healthy tissues, leading to off-target effects and reduced efficacy. Traditional ADC development struggles with rapidly generating and screening novel therapeutic candidates with complex structures and diverse target combinations.
Solution
Valink addresses these challenges with its LiliumX™ platform, a multidimensional drug discovery engine for bispecific antibody-drug conjugates (bsADCs). The platform enables rapid and iterative construction of drug candidate libraries from antibody fragments and small molecules. By targeting two cellular markers simultaneously, Valink's bsADCs improve payload delivery and more accurately differentiate between malignant and healthy tissues, enhancing the specificity and effectiveness of cancer treatments. The platform facilitates the design and testing of bsADCs with complex structures and diverse target and payload combinations at an accelerated pace.
Target Audience
Valink's primary target audience includes pharmaceutical companies and research institutions focused on developing novel cancer therapeutics, particularly those specializing in antibody-drug conjugates and bispecific antibodies.
Features
- Rapid design and iterative construction of drug candidate libraries.
- Utilizes a variety of components, including antibody fragments and small molecules.
- Focuses on bispecific antibody-drug conjugates (bsADCs) for solid tumors.
- Aims at two cellular markers simultaneously to differentiate malignant from healthy tissue.
- High-throughput phenotypic screening to discover hidden synergies.